<DOC>
	<DOCNO>NCT02273154</DOCNO>
	<brief_summary>This Multicenter , open lable , parallel randomize controlled clinical trial . This study aim evaluate treatment onset time , efficacy safety patient major depressive disorder , accompany anxiety receive Buspirone Paroxetine .</brief_summary>
	<brief_title>Randomized，Controlled Open-label Study Buspirone add-on Treatment Patients With Major Depression Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Buspirone</mesh_term>
	<criteria>1 . Patients meet Statistical Manual Mental Disorders IV ( DSMIV ) criteria major depression disorder , Hamilton Depression Rating Scale ( HAMD ) score 17 , Hamilton Anxiety Scale（HAMA）score 7 . 2. aged 1865 year ( include 18,65 year ) 3. male female inpatient well outpatient . 4 . Written inform consent obtain patient therapy . 1 . Patients pregnant breastfeed take effective contraceptive measure 2 . Patients allergic buspirone know intolerance contraindication 3 . Patients clinically severe unstable disease , suitable participate study judge investigator 4 . Patients nervous system disease ( epilepsy , Brain injury , Multiple Sclerosis , Degenerative disease include acute lateral sclerosis , Parkinson 's disease , ataxy ) 5 . Patients mental illness accord DSMIV , Organic mental disorder , Schizophrenia , Shizoaffective disorder , delusional disorder , Undifferentiated schizophrenia , bipolar disorder , patient history substance abuse include alcohol active drug within 12 month screen . 6 . Patients take Psychiatric drug ( Antipsychotic drug , Anticonvulsant Mood stabilizer include Antihistamine agent ) receive ECT might exclude . 7 . Patients work professional driver dangerous work 8 . Patients participate clinical trial within past 30 day treat drug sponsor eligible . 9 . Patients clinically significant abnormality electrocardiogram laboratory test 10 . Patients Acute Angleclosure Glaucoma 11 . Patients Myasthenia Gravis 12 . Patients used Monoamine oxidase inhibitor ( MAOI ) within 2 week Screening 13 . Patients Refractory depression invalid nonresponsive adequate dosage ( therapeutic dose upper limit ) duration ( 6 week ) two different antidepressant . 14 . Patients pose suicidal risk , HAMD suicide score 3 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>major depressive disorder</keyword>
	<keyword>Efficacy safety buspirone add-one treatment patient major depression disorder</keyword>
	<keyword>buspirone</keyword>
	<keyword>paroxetine</keyword>
	<keyword>anxiety</keyword>
</DOC>